Patient P-02433

Synthetic patientMETA-24 · Day 164 · 25–34 · M · baseline S07Open companion preview

Therapy response

Favorable

Tolerance

Stable

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

65%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S07
Day 122 GI-04 recommended — GI Support Protocol GI-04
Day 123 Patient accepted — Started GI-04 in the companion
Day 131 GI symptom burden −23% vs expected — GI Support Protocol GI-04
Day 135 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 137 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 135.

Primary contributors, last 14 days

Nutritional resilience-16
GI instability+13
Treatment adherence-12
Inflammatory activity-3

What helped?

GI Support Protocol GI-04Day 122
Result: symptom burden −23%

LIFE OS recommendation

Monitoring Escalation ME-01

77%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 51 and rising
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓40
- BloodInflammatory load index 46
- WearableHRV 17 ms, trending down
Autonomic recovery ↓40
- Wearable1,885 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3.1 · butyrate capacity 39/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 25 ms
Sleep: 6.6 h
Steps: 2,118
Resting HR: 69 bpm

Daily log: GI score 51, nutritional resilience 39, adherence 67.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02334	51%	S04	GI-04	improved	66
P-02240	44%	S20	GI-04	improved	57
P-02054	41%	S01	CR-01	improved	57
P-02151	38%	S04	CR-01	improved	49
P-02508	38%	S14	ME-01	improved	51
P-02149	37%	S14	GI-04	improved	50
P-02216	37%	S11	GI-04	improved	53
P-02233	37%	S16	CR-01	improved	66
P-02236	37%	S14	GI-04	improved	45
P-02009	36%	S08	CR-01	improved	64
P-02060	36%	S14	GI-04	improved	54
P-02125	36%	S14	GI-04	improved	55